Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, and Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer are the three ADCs that Seagen is currently commercializing.
Padcev is a Nectin-4-directed antibody and microtubule inhibitor combination that is currently approved for third-line metastatic urothelial cancer treatment. However, the companies want to advance this drug to the front line. Ongoing registrational trials for PADCEV in the first-line metastatic setting are supported by pre...
